Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
Actinium presented new preclinical data at EANM 2026 showing ATNM-400, its HER3-targeted Actinium-225 radioconjugate, has broad antitumor activity across lung, colorectal and ovarian cancer mouse models. Highlights include 81-93% tumor growth inhibition as monotherapy across models, and combinations lifting TGI to 105% in KRAS-mutant lung cancer and 72% in a poorly responsive colorectal model versus 25% for standard therapy.
Key figures
- Drug Name
- ATNM-400 (baredetamab/Actinium-225 HER3 radioconjugate)
- Phase Of Trial
- Phase 1 (first-in-human in mCRPC); new data is preclinical
- Alk combo tgi
- 97%
- Egfr combo tgi
- 86%
- Kras g12c mono tgi
- 81%
- Bevacizumab failure tgi
- 50%
- Ovarian ovcar5 mono tgi
- 93%
- Colorectal hct15 combo tgi
- 72%
- Colorectal standard therapy tgi
- 25%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.